kaonavi
4435
D. Western Therapeutics Institute
4576
Rentracks
6045
Migalo Holdings
5535
Itamiarts
168A
(Q3)Dec 31, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 6.05%77.96B | 9.11%76.65B | 0.82%287.27B | 5.16%71.81B | 0.45%73.51B | -0.07%71.69B | -2.06%70.25B | 8.29%284.94B | 1.64%68.29B | 8.23%73.18B |
Cost of revenue | 5.96%54.06B | 6.85%53.07B | -1.00%201.56B | 1.29%50.1B | -1.15%51.02B | -1.34%50.77B | -2.70%49.67B | 11.43%203.59B | 3.04%49.47B | 11.05%51.62B |
Gross profit | 6.24%23.89B | 14.56%23.59B | 5.36%85.71B | 15.33%21.71B | 4.30%22.49B | 3.17%20.92B | -0.48%20.59B | 1.18%81.35B | -1.85%18.82B | 2.03%21.56B |
Operating expense | 46.50%21.32B | 9.40%15.41B | 3.50%58.51B | 7.39%15.05B | 3.71%14.55B | 1.98%14.82B | 0.95%14.09B | 1.82%56.53B | -8.26%14.01B | 2.63%14.03B |
Selling and administrative expenses | 8.05%15.81B | 11.76%15.68B | 4.20%58.25B | 8.94%14.91B | 5.16%14.63B | 1.46%14.69B | 1.40%14.03B | 3.69%55.91B | -1.52%13.68B | 2.36%13.91B |
-General and administrative expense | 8.05%15.81B | 11.76%15.68B | 4.20%58.25B | 8.94%14.91B | 5.16%14.63B | 1.46%14.69B | 1.40%14.03B | 3.69%55.91B | -1.52%13.68B | 2.36%13.91B |
Other operating expenses | 8,652.31%5.69B | 176.54%224M | -39.98%521M | -37.57%226M | -69.77%65M | 71.26%149M | -60.49%81M | -50.48%868M | -74.45%362M | 64.12%215M |
Total other operating income | 24.11%175M | 2,463.16%487M | 8.23%263M | 159.38%83M | 50.00%141M | -42.86%20M | -76.83%19M | 62.00%243M | -11.11%32M | 91.84%94M |
Operating profit | -67.57%2.57B | 25.75%8.17B | 9.58%27.2B | 38.46%6.66B | 5.39%7.94B | 6.16%6.1B | -3.45%6.5B | -0.25%24.82B | 23.27%4.81B | 0.92%7.53B |
Net non-operating interest income (expenses) | 49.01%1.35B | 19.64%1.27B | 124.20%4.29B | 88.41%1.27B | -27.17%906M | 176.32%1.05B | 377.08%1.06B | 92.65%1.91B | 252.36%673M | 239.89%1.24B |
Non-operating interest income | -2.09%1.13B | 14.09%1.34B | 93.09%4.61B | 53.24%1.32B | -13.85%1.15B | 146.58%1.12B | 138.95%1.18B | 84.97%2.39B | 236.19%864M | 205.02%1.34B |
Non-operating interest expense | -191.02%-223M | -37.72%71M | -32.21%322M | -70.68%56M | 166.30%245M | -8.22%67M | -87.00%114M | 59.40%475M | 189.39%191M | 27.78%92M |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | ||||||||||
Other non-operating income (expenses) | ||||||||||
Income before tax | -55.63%3.92B | 24.87%9.45B | 17.78%31.49B | 44.59%7.93B | 0.79%8.84B | 16.69%7.15B | 19.16%7.56B | 3.31%26.74B | 33.93%5.48B | 12.07%8.77B |
Income tax | 98.63%3.76B | 33.63%2.42B | 55.47%9.55B | 209.08%4.08B | 7.37%1.89B | 14.60%1.76B | 19.19%1.81B | -14.93%6.14B | -27.18%1.32B | -6.96%1.76B |
Net income | -97.68%161M | 22.10%7.02B | 6.53%21.94B | -7.64%3.85B | -0.87%6.95B | 17.41%5.4B | 19.15%5.75B | 10.37%20.6B | 82.67%4.16B | 18.15%7.01B |
Net income continuous operations | -97.68%161M | 22.10%7.02B | 6.53%21.94B | -7.64%3.85B | -0.87%6.95B | 17.41%5.4B | 19.15%5.75B | 10.37%20.6B | 82.67%4.16B | 18.15%7.01B |
Noncontrolling interests | 883.33%47M | -44.74%21M | -64.26%109M | 53.57%43M | -107.06%-6M | -55.84%34M | -66.96%38M | -15.51%305M | -76.27%28M | 18.06%85M |
Net income attributable to the company | -98.36%114M | 22.55%7B | 7.60%21.83B | -8.03%3.8B | 0.43%6.96B | 18.63%5.36B | 21.25%5.71B | 10.87%20.29B | 91.21%4.13B | 18.15%6.93B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -98.36%114M | 22.55%7B | 7.60%21.83B | -8.03%3.8B | 0.43%6.96B | 18.63%5.36B | 21.25%5.71B | 10.87%20.29B | 91.21%4.13B | 18.15%6.93B |
Gross dividend payment | ||||||||||
Basic earnings per share | -98.37%1.22 | 23.65%75.16 | 8.38%233.66 | -6.94%40.88 | 1.49%74.68 | 19.52%57.4 | 21.44%60.785 | 10.88%215.59 | 91.29%43.93 | 18.16%73.585 |
Diluted earnings per share | -98.37%1.22 | 23.65%75.16 | 8.38%233.66 | -7.06%40.8249 | 1.49%74.68 | 19.52%57.4 | 21.44%60.785 | 10.88%215.59 | 91.28%43.9277 | 18.16%73.585 |
Dividend per share | 0 | 0 | 15.38%75 | 14.29%40 | 0 | 16.67%35 | 0 | 18.18%65 | 16.67%35 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |